EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pitavastatin treatment remodels the HDL subclass lipidome and proteome in hypertriglyceridemia

M John Chapman, Alexina Orsoni, Natalie A Mellett, Anh Nguyen, Paul Robillard, Jonathan E Shaw, Philippe Giral, Patrice Thérond, Debi Swertfeger, W Sean Davidson, Peter J Meikle

Journal of Lipid Research · 2024

DOI: 10.1016/j.jlr.2023.100494 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Lipid Research, 2024. Verfasst von M John Chapman und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Disease Prevention Unit, Pitié-Salpetrière University Hospital, Sorbonne University and National Institute for Health and Medical Rese…. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypertriglyceridemia, Hyperlipidemias, Quinolines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, Kowa Pharmaceutical Europe Co Ltd, Institut National de la Santé et de la Recherche Médicale.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

HDL particles vary in lipidome and proteome, which dictate their individual physicochemical properties, metabolism, and biological activities. HDL dysmetabolism in nondiabetic hypertriglyceridemia (HTG) involves subnormal HDL-cholesterol and apoAI levels. Metabolic anomalies may impact the qualitative features of both the HDL lipidome and proteome. Whether particle content of bioactive lipids and proteins may differentiate HDL subclasses (HDL2b, 2a, 3a, 3b, and 3c) in HTG is unknown. Moreover, little is known of the effect of statin treatment on the proteolipidome of hypertriglyceridemic HDL and its subclasses. Nondiabetic, obese, HTG males (n = 12) received pitavastatin calcium (4 mg/day) for 180 days in a single-phase, unblinded study. ApoB-containing lipoproteins were normalized poststatin. Individual proteolipidomes of density-defined HDL subclasses were characterized prestatin and poststatin. At baseline, dense HDL3c was distinguished by marked protein diversity and peak abundance of surface lysophospholipids, amphipathic diacylglycerol and dihydroceramide, and core cholesteryl ester and triacylglycerol, (normalized to mol phosphatidylcholine), whereas light HDL2b showed peak abundance of free cholesterol, sphingomyelin, glycosphingolipids (monohexosylceramide, dihexosylceramide, trihexosylceramide, and anionic GM3), thereby arguing for differential lipid transport and metabolism between subclasses. Poststatin, bioactive lysophospholipid (lysophosphatidylcholine, lysoalkylphosphatidylcholine, lysophosphatidylethanolamine, and lysophosphatidylinositol) cargo was preferentially depleted in HDL3c. By contrast, baseline lipidomic profiles of ceramide, dihydroceramide and related glycosphingolipids, and GM3/phosphatidylcholine were maintained across particle subclasses. All subclasses were depleted in triacylglycerol and diacylglycerol/phosphatidylcholine. The abundance of apolipoproteins CI, CII, CIV, and M diminished in the HDL proteome. Statin treatment principally impacts metabolic remodeling of the abnormal lipidome of HDL particle subclasses in nondiabetic HTG, with lesser effects on the proteome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsHypertriglyceridemiaHyperlipidemiasQuinolinesMaleHumansProteomeDiglyceridesLipidomicsCeramidesCholesterolCholesterol, HDLTriglyceridesPhosphatidylcholines

Stichwörter der Autor:innen

HDL subclasseslipidomicsmetabolic remodelingnondiabetic hypertriglyceridemiapitavastatin calciumproteomics

Substanzen

dihydroceramidepitavastatinHydroxymethylglutaryl-CoA Reductase InhibitorsProteomeDiglyceridesCeramidesCholesterolCholesterol, HDLTriglyceridesPhosphatidylcholines

Autor:innen und Institutionen

  • Cardiovascular Disease Prevention Unit, Pitié-Salpetrière University Hospital, Sorbonne University and National Institute for Health and Medical Research (INSERM), Paris, France. Electronic address: john.chapman@upmc.fr.
  • Service de Biochimie, AP-HP, Paris-Saclay University, Bicetre University Hospital, and EA 7357, Paris-Saclay University, Orsay, France.
  • Metabolomics Laboratory, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
  • Cardiovascular Disease Prevention Unit, Pitié-Salpetrière University Hospital, Sorbonne University and National Institute for Health and Medical Research (INSERM), Paris, France.
  • INSERM UMR1166 and Cardiovascular Prevention Units, ICAN-Institute of CardioMetabolism and Nutrition, AP-HP, Pitie-Salpetriere University Hospital, Paris, France.
  • Department of Endocrinology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.

Förderung

  • NHLBI NIH HHS
  • Kowa Pharmaceutical Europe Co Ltd
  • Institut National de la Santé et de la Recherche Médicale

Zitieren

APA

Chapman, M. J., Orsoni, A., Mellett, N. A., Nguyen, A., Robillard, P., Shaw, J. E., Giral, P., Thérond, P., Swertfeger, D., Davidson, W. S., & Meikle, P. J. (2024). Pitavastatin treatment remodels the HDL subclass lipidome and proteome in hypertriglyceridemia. Journal of Lipid Research. https://doi.org/10.1016/j.jlr.2023.100494

Vancouver

Chapman MJ, Orsoni A, Mellett NA, Nguyen A, Robillard P, Shaw JE, et al. Pitavastatin treatment remodels the HDL subclass lipidome and proteome in hypertriglyceridemia. Journal of Lipid Research. 2024. doi:10.1016/j.jlr.2023.100494

BibTeX
@article{Chapman2024,
  author = {Chapman, M John and Orsoni, Alexina and Mellett, Natalie A and Nguyen, Anh and Robillard, Paul and Shaw, Jonathan E and Giral, Philippe and Thérond, Patrice and Swertfeger, Debi and Davidson, W Sean and Meikle, Peter J},
  title = {Pitavastatin treatment remodels the HDL subclass lipidome and proteome in hypertriglyceridemia},
  journal = {Journal of Lipid Research},
  year = {2024},
  doi = {10.1016/j.jlr.2023.100494}
}
Kostenlos starten →